IP Library Granted Patent US 7,053,193
Granted Patent B2
US 7,053,193 · App. 10/054,935 · Granted May 30, 2006

Breast cancer transcription factor gene and uses

Assignee: Origene Technologies, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,053,193
App. No.
10/054,935
Granted
May 30, 2006
Kind
B2
Abstract

The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science and medicine, etc. The polynucleotides, Urb-ctf, are expressed in breast cancer and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions especially related to breast cancer.

Claims (29)

1. An isolated polynucleotide, comprising a polynucleotide sequence which codes without interruption for human Urb-ctf comprising amino acids 1–614 as set forth in SEQ ID NO 2, or the complete complement thereto.

2. An isolated polynucleotide of claim 1 , comprising the polynucleotide sequence from nucleotide positions 78–1922 as set forth in SEQ ID NO 1, or the complete complement thereto.

3. An isolated human polynucleotide, comprising a

polynucleotide sequence which codes without interruption for a full-length human Urb-crf having 614 amino acids, which has transcriptional regulatory activity, and which hybridizes to the complete complement of SEQ ID NO: 1 from nucleotide positions 78–1922 under high stringency conditions comprising overnight incubation in 5×SSC, 0.5% SDS, 100 μg/ml denatured salmon sperm DNA and 50% formamide, at 42° C., followed by washing in 0.1% SSC and 0.1% SDS for 30 min at 65° C.

4. An isolated polynucleotide consisting of a polynucleotide sequence selected from SEQ ID NO 1 wherein said polynucleotide comprises at least 15 nucleotides and codes for a fragment of SEQ ID NO:2 which comprises

amino acid 38 of SEQ ID NO 2,

amino acid 68 of SEQ ID NO 2,

amino acids 76–77 of SEQ ID NO 2,

amino acid 119 of SEQ ID NO 2,

amino acid 143–144 of SEQ ID NO 2,

amino acid 161 of SEQ ID NO 2,

amino acid 583 of SEQ ID NO 2, or

amino acid 606 of SEQ ID NO 2; or

the complete complement thereof.

5. An isolated polynucleotide of claim 4 , which is a polynucleotide coding for coding for amino acids 1–263 of SEQ ID NO 2 or 459–614 of SEQ ID NO 2, or a the complete complement thereof.

6. An isolated polynucleotide of claim 4 , wherein said polynucleotide is effective in a polymerase chain reaction.

7. An isolated polynucleotide of claim 4 , which codes for a polypeptide comprising at least eight amino acids in length.

8. An isolated polynucleotide of claim 1 , comprising the polynucleotide sequence from nucleotide positions 1–4372 as set forth in SEQ ID NO 1, or the complete complement thereto.

9. An isolated polynucleotide of claim 4 , which comprises at least 24 nucleotides.

10. An isolated polynucleotide of claim 4 , which comprises at least 30 nucleotides.

11. An isolated polynucleotide of claim 4 , which comprises at least 45 nucleotides.

12. A method of producing human Urb-ctf polypeptide, comprising

expressing a polynucleotide of claim 1 which codes without interruption for said polypeptide and which is operably linked to an expression control sequence under conditions effective to achieve production of said polypeptide coded for by said polynucleotide.

13. A method of producing human Urb-ctf polypeptide, comprising

expressing a polynucleotide of claim 1 which codes without interruption for said polypeptide and which is operably linked to an expression control sequence under conditions effective to achieve production of said polypeptide coded for by said polynucleotide.

14. A method of producing human Urb-ctf polypeptide, comprising

expressing a polynucleotide of claim 3 which codes without interruption for said polypeptide and which is operably linked to an expression control sequence under conditions effective to achieve production of said polypeptide coded for by said polynucleotide.

15. A method of producing human Urb-ctf polypeptide, comprising:

expressing a polynucleotide of claim 8 which codes without interruption for said polypeptide and which is operably linked to an expression control sequence under conditions effective to achieve production of said polypeptide coded for by said polynucleotide.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 3, 2018
From: MANUFACTURERS AND TRADERS TRUST COMPANY
To: ORIGENE TECHNOLOGIES, INC.
Reel/Frame 047651/0723 →
SECURITY INTEREST Recorded Nov 17, 2017
From: ORIGENE TECHNOLOGIES, INC.
To: MANUFACTURERS AND TRADERS TRUST COMPANY
Reel/Frame 044159/0342 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2006
From: BAUER, KARL-HEINZ
To: BORGWARNER INC.
Reel/Frame 017288/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2003
From: SUN, ZAIREN; FAN, WUFANG; KOVACS, IV, KARL R.; LI, XUAN; JAY, GILBERT
To: ORIGENE TECHNOLOGIES, INC.
Reel/Frame 014643/0829 →
Continuity (1)
Related Publication 20030143546A1 · Jul 31, 2003